Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is well-positioned for growth with the commercial success of its three products, Afrezza, Furoscix, and V-Go, and the potential for additional indications within their pipeline. The company's strong partnerships with United Therapeutics and others, combined with multiple catalysts such as the potential approval of ReadyFlow and pediatric Afrezza, make it a compelling investment opportunity. Additionally, the recent positive commentary from UTHR on the potential for their Tyvaso DPI in IPF, as well as the pursuit of ralinepag DPI, further strengthens confidence in MannKind's royalty revenue stream. Overall, MannKind has a positive outlook with potential for significant revenue growth in the coming years.

Bears say

MannKind is reporting disappointing quarterly revenue and EPS numbers, with revenues falling short of analyst expectations and a negative EPS. The company has also not met previous revenue targets for Furoscix and is relying heavily on upcoming catalysts, such as the pediatric PDUFA for Afrezza and Phase 1b data for MNKD-201, to drive growth. However, there are concerns over the tolerability of MNKD-201 in IPF patients and potential delays in Phase 2. The company's cash and investment position has improved, but there are still uncertainties surrounding its future financial stability if these upcoming catalysts do not meet expectations.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.